Determination Of FEZ1/LZTS1 Expression As A Predictor Of Response To Taxol
- Determine whether loss of function of the FEZ1/LZTS1 gene is a predictor of response in
patients with breast cancer treated with paclitaxel.
OUTLINE: This is a single-blind study.
Tumor tissue is analyzed for FEZ1/LZTS1 gene expression by immunohistochemistry using an
antibody for the gene. Tumor expression of the gene is characterized by immunohistochemistry
and scored by intensity of staining, percent of cell staining, and staining index. Tumor
tissue is also analyzed for FEZ1/LZTS1 gene disruption by reverse transcriptase-polymerase
chain reaction and direct sequencing.
PROJECTED ACCRUAL: Approximately 120 patients will be accrued for this study.
Evaluation of the association between tumor expression of FEZ1/LZTS1 gene and response to paclitaxel
Carlo M. Croce, MD
Kimmel Cancer Center (KCC)
United States: Federal Government